| P/E (FY) | 12.5 | Sales (TTM) | $148.9M |
| Earnings (TTM) | $44.9M | ROE | 58.89% |
| Net Margin | 30.14% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 63.35% |
| Market Cap | $403.9M | Trading Days | 4015 |
| 52W High | 0.74 |
| 52W Low | 0.33 |
| % Off High | −49.32% |
| YTD | −23.47% | 1Y | −31.82% |
| 3Y | 837.50% | 5Y | 650.00% |
| 10Y | 119.30% | Since incept. (ann.) | 7.70% |
Manufacturing 25% · Manufacturing Fees 25% · Scheduled Products Manufacturing Fees 24% · Indirect Sales To Wholesalers 14% · …
| Ann. Volatility (1Y) | 56.38% | Ann. Volatility (3Y) | 81.86% |
| Sharpe (1Y) | −0.41 | Sharpe (3Y) | 1.31 |
| Max Drawdown (1Y) | −52.11% | Max Drawdown (3Y) | −56.12% |
| Beta (3Y, vs SPY) | 0.89 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CAPR | CAPRICOR THERAPEUTICS, INC. | $405.1M | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $406.7M | 13.1 |
| EOLS | Evolus, Inc. | $407.0M | — |
| EVMN | Evommune, Inc. | $409.2M | — |
| LRMR | Larimar Therapeutics, Inc. | $397.9M | — |
| BNTC | Benitec Biopharma Inc. | $397.8M | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $411.8M | — |
| KROS | Keros Therapeutics, Inc. | $386.5M | 4.4 |
| AVIR | Atea Pharmaceuticals, Inc. | $385.7M | — |
| EBS | Emergent BioSolutions Inc. | $378.2M | 7.9 |
| OVID | Ovid Therapeutics Inc. | $438.6M | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $370.2M | — |
